How to Read a Peptide Certificate of Analysis: A Field Guide
CoAs verify peptide purity by reporting the result of a reversed-phase HPLC run, where purity is the area of the main peptide peak as a percentage of every UV-absorbing species the detector sees at 210 to 220 nm. As the chemist who signs off batch release at Healius, I read these documents every week. A good Certificate of Analysis has six sections, each answering a different question. This guide walks all six, using a real lot, and flags what should make you put a vial back.
What does a Certificate of Analysis actually verify?
A Certificate of Analysis verifies that a specific batch meets its specification for identity, purity, and content, and is traceable to a single lot. It is a release document, not a marketing sheet. Six sections carry the weight: the header and batch ID, the appearance line, the HPLC purity result, the mass spectrometry identity confirmation, the third-party verification block, and the release signature.
The header ties everything to one lot number, one manufacture date, and one set of test conditions. That lot number has to match the number printed on the vial in your hand. If it does not, the document describes a different batch and tells you nothing about your material. International quality frameworks such as ICH Q6A treat identity, purity, and assay as three separate questions, each with its own acceptance criterion [1]. A CoA that collapses them into a single “tested” stamp has skipped the work. You can see how we structure each field on our in-house and third-party lab testing page, where every batch links to its own certificate.
How do CoAs verify peptide purity, and what does the HPLC number mean?
HPLC purity is the area of the main peptide peak, expressed as a percentage of the total area of all peaks recorded by the UV detector, typically at 210-220 nm. A 99.2% result means the target peptide accounts for 99.2% of the UV-absorbing material; the remaining 0.8% is synthesis-related impurities such as truncated or deletion sequences, oxidation products, and incomplete-deprotection adducts [2]. For research-grade peptides, 99% is the right minimum, and it is the specification I hold every Healius batch to.
One number is not the whole story, which is why the chromatogram matters. Purity tells you the peptide-versus-impurity ratio. It does not tell you the net peptide content, which is the peptide mass relative to everything else in the vial: water, residual salts, and counterions. A peptide can read 99% pure on HPLC yet be only 70 to 85% net content by mass because the chromatogram does not detect water or counterions at that wavelength [3]. Reading the chromatogram alongside the purity figure helps you catch co-eluting impurities that a single percentage can hide; orthogonal methods exist precisely because a single separation can mask structurally similar degradants [4]. The angiogenic pathway studied in healing-peptide research depends on that material being what the label says, which is why the lot behind a product such as BPC-157 carries its own chromatogram, not a borrowed one.
Identity, water, and counterion: the sections buyers skip
Mass spectrometry confirms identity by comparing the peptide’s measured mass with its theoretical mass, typically to within 5 ppm on a high-resolution instrument. HPLC tells you how much of one thing you have; it does not prove the thing is the right sequence. Only mass spectrometry does that, and a deamidation event as small as a single 0.984 Da shift is enough to flag the wrong species [5]. The CoA should show both the theoretical and the found mass, with a difference close enough that the match is unambiguous.
Two more sections get skipped, and both change how a vial behaves at the bench. Water content by Karl Fischer titration indicates how much moisture the lyophilized powder contains, because water drives hydrolytic degradation throughout a product’s shelf life [1]. Counterion content, measured by ion chromatography, reports whether the peptide carries trifluoroacetate (molecular weight 114) or acetate (molecular weight 59) left over from synthesis, and that mass is part of why net content sits below purity [6][7]. The appearance line matters too: a clear reconstituted solution suggests the peptide is intact, whereas cloudiness indicates aggregation, often due to a rough temperature history or freeze-thaw cycling [8]. If the appearance reads cloudy, the storage questions covered in our reconstitution and storage guide are the first thing to check.
What are the red flags, and why does dual testing matter?
The clearest red flag is a CoA you cannot trace: no lot number, no test conditions, a result of exactly 100.00%, or a certificate that cannot be matched to your vial. Real analytical data is never perfectly round, and a document without a release signature has no accountable person standing behind it. A shared or recycled CoA, reused across batches or vendors, tells you nothing about the material you actually received.
Dual testing exists because in-house and independent labs catch different things. In-house quality control runs every batch, builds method history, and flags trends fast. An independent third-party laboratory removes the conflict of interest and verifies the result on instruments the manufacturer does not control; at Healius, that partner is Janoshik, an independent third-party laboratory in the United States. This matters beyond paperwork. In one 2024 immunogenicity study, synthesis-related impurities at just 0.24 to 3.30% of peptide content introduced new T-cell epitopes absent from the pure compound [9], and current FDA peptide-impurity guidance expects every peptide impurity above 0.10% to be identified [10]. That is the real reason the purity threshold is not cosmetic. You can read how both layers work together on our lab testing page.
References
1. McCarthy D, Han Y, Carrick K, et al. Reference standards to support the quality of synthetic peptide therapeutics. Pharm Res. 2023;40(6):1317-1328. DOI: 10.1007/s11095-023-03493-1. PMID: 36949371.
2. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. DOI: 10.1016/j.jpba.2014.06.012. PMID: 25044089.
3. Zeng K, Geerlof-Vidavisky I, Gucinski A, Jiang X, Boyne MT 2nd. Liquid chromatography-high resolution mass spectrometry for peptide drug quality control. AAPS J. 2015;17(3):643-651. DOI: 10.1208/s12248-015-9730-z. PMID: 25716148.
4. Ntorkou M, Zacharis CK. Applications of hydrophilic interaction chromatography in pharmaceutical impurity profiling: a comprehensive review of two decades. Molecules. 2025;30(17):3567. DOI: 10.3390/molecules30173567. PMID: 40942092.
5. Zeng K, Geerlof-Vidavisky I, Gucinski A, Jiang X, Boyne MT 2nd. Liquid chromatography-high resolution mass spectrometry for peptide drug quality control. AAPS J. 2015;17(3):643-651. DOI: 10.1208/s12248-015-9730-z. PMID: 25716148.
6. Mrozik W, Kotłowska A, Kamysz W, Kowalski P, Kupryszewski G, Wiczling P, et al. Determination of counter-ions in synthetic peptides by ion chromatography, capillary isotachophoresis, and capillary electrophoresis. J Pept Sci. 2012;18(3):192-198. DOI: 10.1002/psc.1436.
7. Kaiser E, Rohrer J. Determination of residual trifluoroacetate in protein purification buffers and peptide preparations by ion chromatography. J Chromatogr A. 2004;1039(1-2):113-117. DOI: 10.1016/j.chroma.2004.03.044. PMID: 15250411.
8. Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. DOI: 10.1098/rsfs.2017.0030. PMID: 29147559.
9. Roberts BJ, Mattei AE, Howard KE, Weaver JL, Liu H, Lelias S, et al. Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods. Front Pharmacol. 2024;15:1363139. DOI: 10.3389/fphar.2024.1363139. PMID: 39185315.
10. Puig M, Shubow S. Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors. Front Immunol. 2025;16:1608401. DOI: 10.3389/fimmu.2025.1608401. PMID: 40607385.
Research Use Only Disclaimer
Healius Peptides products are sold for in vitro research use only and are not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.
Frequently Asked Questions About Peptide Certificates of Analysis
For most research use, 99% by reversed-phase HPLC is the appropriate minimum, and many sensitive assays benefit from it. Discovery-phase work often tolerates 95 to 98%, but below 95% the impurity load can confound results. The figure should always be read alongside the chromatogram and the net peptide content.
Purity is the peptide measured against other peptide-related impurities, expressed as a percentage of UV-absorbing material on HPLC. Net peptide content is the actual peptide mass relative to everything else in the vial, including water, salts, and counterions. A peptide can be 99% pure yet only 70 to 85% net content by mass.
Mass spectrometry confirms identity by matching the measured accurate mass to the theoretical mass, usually within 5 ppm. HPLC quantifies the amount of a compound present, but cannot prove the sequence is correct. The two methods are complementary: one measures the amount, the other identifies the compound.
In-house testing runs on every batch, builds a method history, and quickly catches trends. Independent third-party testing removes any conflict of interest and confirms results on instruments the supplier does not control. Using both means, routine problems are caught early, and the ones that in-house work might miss are still flagged.
Yes. A Certificate of Analysis describes one specific batch, identified by its lot number. If the lot number on the certificate does not match the number on your vial, the document refers to different material and does not characterize what you hold. Lot traceability is the foundation of the whole document.
The appearance line records the product at release, usually as a white lyophilized powder that yields a clear solution upon reconstitution. If your reconstituted solution appears cloudy despite a clean appearance result, suspect aggregation due to temperature excursions or repeated freeze-thaw cycles after dispatch rather than a manufacturing fault.
Leave a Reply